Palomino Laboratories (PALX) Cash & Equivalents (2022 - 2025)

Palomino Laboratories has disclosed Cash & Equivalents across 4 years of filings, most recently posting $8.1 million for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $8.1 million, up 5931.21% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.1 million (up 5931.21% YoY), and the FY2025 annual result was $8.1 million, up 5931.21% from the prior year.
• Cash & Equivalents came in at $8.1 million for Q4 2025 at Palomino Laboratories, up from $7.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $8.1 million in Q4 2025 to a low of $322.0 in Q2 2024.
• The 4-year median for Cash & Equivalents is $500.0 (2022), against an average of $1.3 million.
• Across the five-year window, Cash & Equivalents slumped 35.6% in 2024 and soared 2452250.62% in 2025, its largest moves.
• Palomino Laboratories' Cash & Equivalents stood at $500.0 in 2022, then decreased by 24.0% to $380.0 in 2023, then surged by 35336.05% to $134657.0 in 2024, then surged by 5931.21% to $8.1 million in 2025.
• The last three Cash & Equivalents figures came in at $8.1 million (Q4 2025), $7.9 million (Q3 2025), and $1887.0 (Q2 2025), per Business Quant data.